Mirati Therapeutics Inc (NASDAQ:MRTX) Director Michael G. Grey sold 5,760 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $65.30, for a total value of $376,128.00. Following the completion of the sale, the director now directly owns 7,100 shares in the company, valued at approximately $463,630. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Mirati Therapeutics stock traded down $3.68 during trading hours on Wednesday, reaching $63.50. 930,735 shares of the company’s stock were exchanged, compared to its average volume of 649,017. Mirati Therapeutics Inc has a 52-week low of $28.50 and a 52-week high of $80.00. The firm has a market cap of $2.29 billion, a PE ratio of -19.91 and a beta of 1.95.
Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.20). The business had revenue of $1.24 million during the quarter. On average, analysts forecast that Mirati Therapeutics Inc will post -5 EPS for the current fiscal year.
A number of research firms recently issued reports on MRTX. Zacks Investment Research lowered Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. BidaskClub raised Mirati Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. Svb Leerink reissued an “outperform” rating on shares of Mirati Therapeutics in a research note on Friday, February 15th. Cowen reissued a “buy” rating on shares of Mirati Therapeutics in a research note on Wednesday. Finally, JPMorgan Chase & Co. began coverage on Mirati Therapeutics in a research note on Wednesday, April 17th. They set a “neutral” rating and a $72.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $69.08.
Several institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC increased its holdings in shares of Mirati Therapeutics by 88.6% during the 1st quarter. Janus Henderson Group PLC now owns 2,034,744 shares of the biotechnology company’s stock worth $149,147,000 after buying an additional 956,022 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Mirati Therapeutics by 30.0% during the 4th quarter. BlackRock Inc. now owns 2,052,949 shares of the biotechnology company’s stock worth $87,086,000 after buying an additional 474,097 shares during the last quarter. TimesSquare Capital Management LLC acquired a new stake in shares of Mirati Therapeutics during the 1st quarter worth $17,687,000. Goldman Sachs Group Inc. increased its holdings in shares of Mirati Therapeutics by 294.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 305,829 shares of the biotechnology company’s stock worth $22,418,000 after buying an additional 228,312 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Mirati Therapeutics by 21.8% during the 4th quarter. Jennison Associates LLC now owns 1,216,464 shares of the biotechnology company’s stock worth $51,602,000 after buying an additional 217,960 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “Michael G. Grey Sells 5,760 Shares of Mirati Therapeutics Inc (MRTX) Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2019/05/15/michael-g-grey-sells-5760-shares-of-mirati-therapeutics-inc-mrtx-stock.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.
Featured Article: Do stock splits help investors?
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.